Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

BMC Public Health

Sandrine I Samson⁴  Francis Shupo²  Abraham Palache¹  Brigitte Sloesen³  Norbert Farkas⁵  Bérengère Macabeo⁶  Laure Durand⁶  Emmanuelle Preaud⁴ 

[1] Abbott, C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands;Creativ-Ceutical Ltd, The Bank Chambers, Borough High Street, London SE1 9QQ, UK;GlaxoSmithKline, Rue de l’Institut 89, Rixensart, Belgium;Sanofi Pasteur MSD, 162 av Jean Jaures, Lyon 69367, France;Novartis Vaccines & Diagnostics AG, Lichtstrasse 35, 4056 Basel, Switzerland;Sanofi Pasteur, 2, Avenue Pont Pasteur, Lyon 69007, France

关键词: Epidemiology;    Modeling;    Vaccines and immunization;    Public health policy;    Influenza;   

Others  :  1128740
DOI  :  10.1186/1471-2458-14-813

 received in 2013-11-13, accepted in 2014-07-29,  发布年份 2014

【 摘 要 】

Background

Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels.

Methods

A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 – 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data.

Results

Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza- related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional + €190 to + €226 million yearly, in vaccination target groups.

Conclusions

Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014–2015 influenza season could immediately reduce an important public health and economic burden.

【 授权许可】

   
2014 Preaud et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organization: Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 2012, 47:461-476.
• [2]World Health Organization: Influenza seasonal. [http://www.who.int/mediacentre/factsheets/fs211/en/ webcite]
• [3]European Centers for Disease Prevention and Control: Stockholm: ECDC Comment 24th Sept 2010 on: Revised estimates of deaths associated with seasonal influenza in the US. [http://www.ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=394 webcite]
• [4]de MS Lopez-Cuadrado T, Jimenez-Jorge S, Savulescu C, Larrauri A: Influenza-related mortality in Spain, 1999–2005. Gac Sanit 2012, 26:325-329.
• [5]Kyncl J, Prochazka B, Goddard NL, Havlickova M, Castkova J, Otavova M, Kriz B: A study of excess mortality during influenza epidemics in the Czech Republic, 1982–2000. Eur J Epidemiol 2005, 20:365-371.
• [6]European Scientific Working Group on Influenza: Seasonal flu – economic impact. [http://flucentre.net/knowledge-centre/seasonal-flu/economic-impact webcite]
• [7]Ryan J, Zoellner Y, Gradl B, Palache B, Medema J: Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006, 24:6812-6822.
• [8]European Centers for Disease Prevention and Control: Stockholm: Influenza season 2012–2013 is over in Europe. [http://ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?List=8db7286c-fe2d-476c-9133-18ff4cb1b568&ID=96 webcite]
• [9]World Health Organization: Review of the 2012-2013winter influenza season, northern hemisphere. Wkly Epidemiol Rec 2013, 22:225-232.
• [10]Groupe Regionaux d’Observation de la Grippe: Bilan de la saison grippale 2012–2013. 2013.
• [11]Grippe: l’épidémie exceptionnelle va coûter cher à la Sécurité sociale [http://www.lesechos.fr/22/02/2013/LesEchos/21382-018-ECH_grippe---l-epidemie-exceptionnelle-va-couter-cher-a-la-securite-sociale.htm webcite]
• [12]La grippe de cet hiver aura coute plus de 200 millions d’Euros: La grippe de cet hiver aura coute plus de 200 millions d’Euros. [http://www.lesechos.fr/26/03/2013/lesechos.fr/0202666032156_la-grippe-de-cet-hiver-aura-coute-plus-de-200-millions-d-euros.htm webcite]
• [13]Commission of the European Communities: Proposal for a council recommendation on seasonal influenza vaccination. [http://www.epha.org/IMG/pdf/seasonflu_rec2009_en.pdf webcite]
• [14]Bridges CB, Katz JM, Levandowski RA, Cox NJ: Inactivated influenza vaccines. In Vaccines. 5th edition. Edited by Plotkin SA, Orenstein WA, Offit PA. Philadelphia: Saunders Elsevier; 2008:259-290.
• [15]Nicoll A, Sprenger M: Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Infect Dis 2013, 13:7-9.
• [16]The Council of the European Union: Council recommendation of 22 December 2009 on seasonal influenza vaccination. [http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF webcite]
• [17]Organization for Economic Co-operation and Development: Health at a Glance Europe. 2012. [http://ec.europa.eu/health/reports/docs/health_glance_2012_en.pdf webcite]
• [18]Noori T: Monitoring the implementation of the Council recommendation on seasonal influenza vaccination (2009/1019/EU). [http://ecdc.europa.eu/en/press/events/Documents/Monitoring-Council-Recommendation-Seasonal-Influenza-Vaccination.pdf webcite]
• [19]VENICE II Consortium: Vaccination coverage assessment in EU/EEA, 2011. [http://venice.cineca.org/Final_Vaccination_Coverage_Assesment_Survey_2011_1.pdf webcite]
• [20]VENICE II Consortium: Final report seasonal influenza vaccination survey in EU/EEA, influenza season 2009–10. [http://venice.cineca.org/Final_Seasonal_Influenza_Vaccination_Survey_2010.pdf webcite]
• [21]VENICE Research Team: Final report national seasonal influenza vaccination survey in Europe. 2007. [http://www.google.ca/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=3&ved=0CD8QFjAC&url=http%3A%2F%2Fvenice.cineca.org%2FInfluenza_Study_Report_v1.0.pdf&ei=cj5vUp_nCerWyQHZg4DgCw&usg=AFQjCNEDFnojrPtelEe3cN8xLAqKOmpF6Q&bvm=bv.5512311 5,d.aWc webcite]
• [22]Eurostat: European community statistics. 2008. [http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home webcite]
• [23]Kroneman M, Van Essen GA, John PW: Influenza vaccination coverage and reasons to refrain among high-risk persons in four European countries. Vaccine 2006, 24:622-628.
• [24]Mereckiene J, Cotter S, Nicoll A, Lévy-Bruhl D, Ferro A, Tridente G, Zanoni G, Berra P, Salmaso S, O’Flanagan D: National Seasonal Influenza Vaccination Survey in Europe, 2008. Euro Surveill 2008, 13:1-7.
• [25]Mereckiene J, Cotter S, Weber JT, Nicoll A, Lévy-Bruhl D, Ferro A, Tridente G, Zanoni G, Berra P, Salmaso S, O’Flanagan D: Low coverage of seasonal influenza vaccination in the elderly in many European countries. Euro Surveill 2008, 13:2-4.
• [26]Blank PR, Schwenkglenks M, Szucs TD: Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect 2009, 58:446-458.
• [27]Mereckiene J, Cotter S, D’Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, Lopalco PL, Weber JT, Johansen K, Dematte L, Salmaso S, Stefanoff P, Greco D, Dorleans F, Polkowska A, O’Flanagan D: Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008–2009. Euro Surveill 2010, 15:11-20.
• [28]Gobierno de Espana, Ministerio de Sanidad, Servicios Sociales, e Igualidad: Coberturas de Vacunación. Datos Estadisticos. 2010. [http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm webcite]
• [29]Emborg HD, Krause TG, Hviid A, Simonsen J, Molbak K: Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009–10. BMJ 2012, 344:d7901.
• [30]Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Chang PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breece Hall C, Monto AS, Griffin MR, Belongia E, Shay DK, USFlu-VE, Network: Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012, 55(7):951-959.
• [31]Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O’Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jimenez-Jorge S, Savulescu C, Ciancio BC, Moren A: I-MOVE multicenter case control study 2010–2011: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 2011, 6:e27622.
• [32]Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jimenez-Jorge S, Horvath JK, Daviaud I, Guiomar R, Necula G, Bella A, O’Donnell J, Gluchowska M, Ciancio BC, Nicoll A, Moren A: Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in europe: results from the i-move multicentre case–control study. Euro Surveill 2013, 18(5):20390.
• [33]Jefferson T, Rivetti A, Di PC, Demicheli V, Ferroni E: Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012, 8:CD004879.
• [34]Jefferson T, Di PC, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010, 7:CD001269.
• [35]Jefferson T, Di PC, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE: Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010, 2:CD004876.
• [36]Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ: Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007, 54:530-538.
• [37]Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E: Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J 2007, 30:1158-1166.
• [38]Zucs P, Buchholz U, Haas W, Uphoff H: Influenza associated excess mortality in Germany, 1985–2001. Emerg Themes Epidemiol 2005, 2:6. BioMed Central Full Text
• [39]Rizzo C, Bella A, Viboud C, Simonsen L, Miller MA, Rota MC, Salmasao S, Ciofi degli Atti ML: Trends for influenza-related deaths during pandemic and epidemic seasons, Italy, 1969–2001. Emerg Infect Dis 2007, 13(5):694-699.
• [40]Health Protection Agency (UK): Surveillance of influenza and other respiratory viruses in the UK, 2010/2011. 2011.
• [41]Gran JM, Iversen B, Hungnes O, Aalen OO: Estimating influenza-related excess mortality and reproduction numbers for seasonal influenza in Norway, 1975–2004. Epidemiol Infect 2010, 138:1559-1568.
• [42]Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Le Gales C, Bungener M, Housset B, Nicolas M, Rouzioux C: Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med 2002, 162:1842-1848.
• [43]Galante M, Garin O, Sicuri E, Cots F, Garcia-Altes A, Ferrer M, Dominguez A, Alonso J: Health services utilization, work absenteeism and costs of pandemic influenza A (H1N1) 2009 in Spain: a multicenter-longitudinal study. PLoS One 2012, 7(2):e31696.
• [44]World Health Organisation: Choosing Interventions that are Cost Effective (WHO-CHOICE). [http://www.who.int/choice/en/ webcite]
• [45]Tarifs des consultations du médecin traitant (applicables au 26 mars 2012) [http://www.ameli.fr/assures/soins-et-remboursements/combien-serez-vous-rembourse/consultations/les-consultations-en-metropole/dans-le-cadre-du-parcours-de-soins-coordonnes.php webcite]
• [46]Garin O, Galante M, García-Altés A, Sicuri E, Cots F, Nebot M, Ferrer M, Dominguez A, Alonso J: Use of Services and Costs of Patients With Flu (H1N1) 2009 In Spain: Background and Research Protocol (In Spanish). Rev Esp Salud Publica 2011, 85:19-31.
• [47]Organization for Economic Co-operation and Development: OECD. StatExtracts. [http://stats.oecd.org/ webcite]
• [48]Lesley Curtis: Unit Costs of Health and Social Care 2011 – PSSRU. [http://www.pssru.ac.uk/project-pages/unit-costs/2012/ webcite]
• [49]Jahnz-Rozyk K: Costs of Treating Infections caused by breathing viruses and pneumonia in the elderly population in Poland (In Polish). 2012.
• [50]Brydak L, Roiz J, Faivre P, Reygrobellet C: Implementing an influenza vaccination programme for adults aged >/=65 years in Poland: a cost-effectiveness analysis. Clin Drug Investig 2012, 32:73-85.
• [51]Anell A, Glenngard AH, Merkur S: Sweden health system review. Health Syst Transit 2012, 14:1-159.
• [52]Pitman RJ, Nagy LD, Sculpher MJ: Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine 2013, 31(6):927-942.
• [53]Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ: Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006, 31:72-79.
• [54]Kostova D, Reed C, Finelli L, Cheng P-Y, Gargiullo PM, Shay DK, Singleton JA, Meltzer MI, Lu P, Bresee JS: Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011. PLoS One 2013, 8(6):e66312.
• [55]Blank PR, Schwenkglenks M, Szucs T: The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly. Hum Vaccin Immunother 2012, 8:328-335.
• [56]Vaccines Europe: Vaccines Europe. [http://www.vaccineseurope.eu/ webcite]
• [57]US Food and Drug Administration: Vaccines, Blood and Biologics – approved products. [http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ucm397090.htm webcite]